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TMEM165 Deficiency Causes
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Protein glycosylation is a complex process that depends not only on the activities of several enzymes and transporters but also on a subtle
balance between vesicular Golgi trafficking, compartmental pH, and ion homeostasis. Through a combination of autozygosity mapping
and expression analysis in two siblings with an abnormal serum-transferrin isoelectric focusing test (type 2) and a peculiar skeletal
phenotype with epiphyseal, metaphyseal, and diaphyseal dysplasia, we identified TMEM165 (also named TPARL) as a gene involved
in congenital disorders of glycosylation (CDG). The affected individuals are homozygous for a deep intronic splice mutation in
TMEM165. In our cohort of unsolved CDG-II cases, we found another individual with the samemutation and two unrelated individuals
with missense mutations in TMEM165. TMEM165 encodes a putative transmembrane 324 amino acid protein whose cellular functions
are unknown. Using a siRNA strategy, we showed that TMEM165 deficiency causes Golgi glycosylation defects in HEK cells.Introduction
Congenital disorders of glycosylation (CDG) are a rapidly
growing family of inborn errors of metabolism. To date,
some 50 different CDG types have been identified,
and most of them affect protein glycosylation (defects
in N-glycosylation, O-glycosylation, and both N- and
O-glycosylation).1–4 Because glycosylation is a ubiquitous
cellular function, it is not surprising that CDG encom-
passes an extremely broad range of clinical phenotypes
and affect every organ system.
Initially, mutations were found in genes encoding
glycosyltransferases, glycosidases, and nucleotide-sugar
transporters. However, CDG types that are caused by defi-
ciencies of vesicular Golgi trafficking5–10 and Golgi pH
homeostasis11 have recently been identified.
For the affected individuals described in this study,
the N-glycan analysis did not allow us to pinpoint the
underlying molecular defect. In addition, a candidate-
gene approach would have been a matter of mere luck
because of the huge number of enzymes and proteins
involved in N-glycosylation as well as in the structure
and function of the Golgi apparatus.
We decided to exploit the possibility of identifying the
candidate gene by a mapping approach, combined with
expression analysis, in a family with two affected siblings
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This strategy led us to identify CDG-II individuals with
mutations in TMEM165.Material and Methods
Cell Culture
Primary skin fibroblasts from healthy controls and affected indi-
viduals and HEK cells were cultured at 37C under 5% CO2 in
DMEM/F12 (Life Technologies) supplemented with 10% fetal
bovine serum (Clone III, HyClones). Where appropriate, microtu-
bule (MT)-depolymerizing drugs nocodazole (5 mM, Calbiochem)
and puromycin (200 mg/ml, Sigma) were added to the cultures.
Research on CDG-affected cells was approved by the ethics
committee of the University of Leuven, and proper informed con-
sent was obtained for affected individuals and family members.
DNA, RNA Extraction, and cDNA Synthesis
Blood DNA was isolated via a classical salt-based extraction proce-
dure. Total RNA was isolated from 2 3 107 fibroblasts with the
TRIzol LS reagent according to the manufacturer’s (Invitrogen)
instructions. TMEM165 cDNAwas prepared with oligo-dT priming
(Amersham) and Superscript III RNase (Invitrogen) according to
the manufacturers’ protocol, and the protein-coding region was
amplified by PCR. Primers were designed by Primer3 to amplify
the entire cDNA as well as the exons on genomic DNA, including
the intron-exon boundaries. Primer sequences, based on the
sequence described in ENSEMBL (ENSG00000134851), areonal Glycobiology Unit, University of Lille 1, Institut Fe´de´ratif de Recherche
etics, de Duve Institute, Universite´ catholique de Louvain, B-1200 Brussels,
Hospital Gasthuisberg, Leuven, B-3000 Leuven, Belgium; 4Laboratory for
000 Leuven, Belgium; 5Molecular Physiology Group, Institut des Sciences
um; 6Departments of Pediatrics and Medical Genetics, Oregon Heath and
adies He´re´ditaires du Me´tabolisme, F-69677 Bron, France; 8Laboratory for
B-3000 Leuven, Belgium; 9Department of Molecular and Developmental
Institute, La Jolla, CA 92037, USA; 11Laboratory of Physiological Chemistry,
Genetics. All rights reserved.
American Journal of Human Genetics 91, 15–26, July 13, 2012 15
available upon request. After purification of the PCR products with
EXO-SAP-IT (Roche), sequencing was performed with the Big Dye
Terminator v.3.1 cycle sequencing kit on ABI 3130xl (Applied Bio-
systems). DNA-mutation numbering is based on the cDNA refer-
ence sequence (RefSeq accession number NM_018475, version
NM_018475.3 GI:195539338).
The sequence variants identified in this study were not found
in 100 controls.
Microarray Analyses
Molecular karyotyping was performed in all six family members
with Affymetrix Human Mapping 50K XbaI SNP chips according
to the manufacturer’s (Affymetrix) instructions. In brief, total
genomic DNA was digested with XbaI, and the 50K fragments
were ligated to adaptors and amplified with a single primer. After
purification of the PCR products, amplicons were quantified, frag-
mented, labeled, and hybridized on the array. Signal intensities
weremeasuredwith AffymetrixGeneChip Scanner 3000 7G.Geno-
types were generated with the Dynamic model.
Copy-Number and Loss-of-Heterozygosity Analyses
Intensity of hybridization was quantified for the estimation of
relative copy numbers for each chromosome. The signal-intensity
ratios of tested samples were divided by the mean of a set of 200
internal reference samples for the calculation of copy-number
status with the use of the Copy-Number Analyzer for GeneChip
(CNAG)12,13 software version 3.3.0.1. Intensity of hybridization
was estimated with the hidden Markov model.
Autozygosity Mapping
Autozygosity refers to the state of a genetic variation in which the
two alleles in an individual are homozygous as a result of being in-
herited from a common ancestor carrying the same allele. Autozy-
gous alleles are commonly described as being identical by descent
(IBD). Autozygosity mapping consists of the following two prin-
cipal steps. (1) A LOD score is computed for each variation per
affected individual. This score indicates how likely the observed
value for a variation results from autozygosity as opposed to being
drawn from a known population. (2) LOD scores are computed for
regions. LOD scores are summed for contiguous variations (on the
same chromosome). Regions are made from the contiguous varia-
tions that have high LOD scores.
Linkage Analysis and Haplotype Analysis
Genome-wide parametric and nonparametric multipoint linkage
analyses were performed in all families with the use of Genspring
GT software (Agilent Technologies). The parametric analyses
were run under an autosomal-recessive mode. The penetrance
was set to 90%, and the phenocopy rate for nongene carriers
was set to 1%. DECODE map was selected for LOD-score calcula-
tion, and the Caucasian population was taken as a reference for
allele frequencies.
Expression Profiling by Microarray Hybridization
RNA extracted from fibroblasts of each family member was used
for gene-expression analysis. The quality of total RNAwas checked
on the basis of A260/A280 ratios (>1.9) and 28S/18S rRNA
peak-height ratios (>1.6), which were determined with a high-
resolution electrophoresis system (Agilent 2100 Bioanalyzer, Agi-
lent Technologies). All microarray procedures followed Human
Genome U133 Plus 2.0 Array (Affymetrix). In brief, 20 mg of16 The American Journal of Human Genetics 91, 15–26, July 13, 2012biotin-labeled cRNA was fragmented according to Affymetrix’s
instructions. All labeled samples were hybridized to Human
Genome U133 Plus 2.0 Array (Affymetrix). GeneChip data
were normalized with MAS 5.0 algorithms, and global normaliza-
tion and scaling were set to a signal intensity of 100. Isolation of
total RNA, synthesis of cRNA, microarray processing, and data
normalization were carried out according to standard Affymetrix
protocols.Data Analysis
A number of quality-control checks were conducted for the evalu-
ation of GeneChip quality. GAPDH was used for the assessment
of the quality of the RNA sample and assay specifically for the
GeneChip array. The signal values for the 30 probe set for GAPDH
were compared to those for the 50 probe set. The ratio of the 30 to
the 50 probe sets was expected to be nomore than 3. Hybridization
controls on the GeneChip array (four E. Coli genes, bioB, bioC,
bioD, and cre) were spiked into each sample independent of RNA-
sample preparation for the evaluation of hybridization efficiency.
Raw noise (Q value), a measure of how pixel-to-pixel variation of
probe cells on a GeneChip array is due to operation-associated
electrical noise of the GeneArray scanner, was evaluated. To serve
as internal controls, PolyA control genes, dap, lys, phe, thr, and trp
from B. subtilis, were amplified and spiked into the RNA samples
prior to amplification. Microarray data were normalized, and
‘‘present,’’ ‘‘marginal,’’ and ‘‘absent’’ calls were made with the
microarray suite v.5 software (MAS5) algorithm in the Affymetrix
package. A probe was removed if it was not expressed in all family
members. In fact, the MAS5 detection call (present or absent) was
used for the removal of 23,914 probe sets (from a total of 54,675
probe sets) that were not reliably detected in all samples.
Principal component analysis (PCA) and hierarchical clustering
(HCL) were applied for the comparison of the whole-genome
gene-expression profiles among the different samples; median
intensity, HCL and K-Medians Support (KMS) were used for the
generation of clusters of genes that frequently group together
across multiple runs and that have a threshold of 80% of occur-
rence in the same cluster.
t Test
Gene expressions were measured with the GeneChip Human
Genome U133 Plus 2.0 Array. A Welch’s t test was performed
with 500 permutations. We set the false discovery rate (FDR) to
5 or the p value to 0.01, and we used standard Bonferonni correc-
tions. The HCL between two affected individuals and controls was
based on Pearson correlation and complete linkage clustering.Significance Analysis of Microarrays
Differential expression between affected members and controls
was investigated with the use of significance analysis of microar-
rays (SAM14). Dynamic tuning of delta parameters and the FDR
give the proportion of genes likely to have been identified by
chance as being significant. We performed two types of testing:
(1) two-class unpaired testing, in which samples fell in one of
two groups and the subjects were different between the two
groups; and (2) two-class paired testing, in which samples were
paired on a one-to-one basis.Integration of Mapping and Expression Data
On the remaining dataset, we used two filteringmethods. First, we
looked for probe sets with a signal more than 1.53 lower in
affected members than in controls; we selected 862 significant
genes, of which 76 were located in the autozygous and linked
regions on chromosomes 4 and 13. Second, 3,000 probe sets
were selected by a maximal standard-deviation filter. Five highly
significant genes came out in all statistical analyses.
Real-Time PCR
Real-time PCR (RT-PCR) in cDNA isolated from control and
TMEM165-deficient cell lines was performed in triplicate with
SYBR green for the detection and quantification of PCR products
on a 7500 RT-PCR system (Applied Biosystems). Hypoxanthine-
guanine phophoribosyltransferase (HPRT) was used as a reference
for the calculation of 2-DDCt.
Mass-Spectrometry Analysis of N- and O-Linked
Glycans Released from Total Plasma Proteins
Analysis of N- and O-linked glycans on plasma glycoproteins
was carried out by surface-enhanced laser desorption/ionization
time-of-flight (TOF) mass spectrometry (Ciphergen) essentially as
described by Foulquier et al., 2007 for matrix-assisted laser
desorption/ionization TOF mass spectrometry (MALDI-TOF-MS).
Analysis of acidic N-linked glycans was performed in linear nega-
tive-ion mode. The total N-linked glycans from plasma proteins
were released enzymatically by PNGase. For O-linked glycans,
the permethylated derivatives were analyzed in positive-ion reflec-
tive mode as [MþNa]þ.The reference samples were anonymous
plasma samples from individuals without CDG or a lysosomal-
storage disease.
Antibodies
Anti-GM130 (mab) and anti-TGN46 (pab) were purchased from
BD Biosciences. Anti-TMEM165 (pab) was from Sigma Aldrich.
Anti-Lamp-2 was purchased from Santa Cruz Biotechnology.
Anti-B4GALT1 (GalT) was a kind gift from E. G. Berger (University
of Zu¨rich, Zu¨rich, Switzerland).
Immunoblotting
For TMEM165 immunoblotting, fibroblasts cells (8 3 106 cells per
sample) were lysed directly in lithium dodecyl sulfate (LDS)
loading buffer (Invitrogen). Samples (20 ml) were separated on
4%–12% Bis-Tris gels (Invitrogen) and transferred to nitrocellulose
membranes (GE Healthcare). Themembrane was blocked in block-
ing buffer (5% milk powder in TBS-T [1X TBS with 0.05%
Tween20]) for 1 hr at room temperature, incubated for the same
amount of time with the primary rabbit anti-TMEM165 antibody
(HPA038299, Sigma-Aldrich; used at a dilution of 1:2,000) in
blocking buffer, and washed three times for 5 min in TBS-T. The
membranes were then incubated with the peroxidase-conjugated
secondary goat anti-rabbit antibody (P0448, Dako; used at a dilu-
tion of 1:10,000) in blocking buffer for 1 hr at room temperature
and later washed three times for 5 min in TBS-T. Signal was
detected with chemiluminescence reagent (ECL, PerkinElmer) on
imaging film (GE Healthcare).
Immunofluorescence Microscopy
Cells were grown on glass coverslips for 12–24 hr, washed once
with PBS, and fixed by being incubated for 25 min with 4% para-
formaldehyde in 0.1 M sodium phosphate buffer (pH 7.2) at room
temperature. The coverslips were rinsed twice with 0.1 M glycine
in PBS for 15 min. The fixed cells were incubated with primary
antibodies for 1 hr.7 After being washed with PBS, Alexa 488- or
Alexa 568-conjugated secondary antibodies (Molecular Probes)Thediluted in blocking solution were applied for 1 hr. Immunostain-
ing was detected through an inverted Leica TCS-SP5 confocal
microscope. Data were collected with Adobe Photoshop 7.0
(Adobe Systems).
Lectin Binding and Flow-Cytometry Assay
Control and siTMEM165-transfected HEK cells were harvested via
pipetting, washed in PBS, fixed with 4% paraformaldehyde in PBS
on ice for 1 hr, and then incubated in 50 mM NH4Cl on ice for
15 min. After two washes with PBS, cells were permeabilized
with 0.5% triton and 0.1% BSA for 10 min at room temperature.
Cells were then washed once in PBS and resuspended to a final
concentration of 1.106 cells/ml in PBS containing 0.1% BSA. All
washing and incubation steps were carried out in the buffered
BSA solution. Forty micrograms of fluorescein isothiocyanate
(FITC)-labeled Sambucus nigra (SNA) was added to 100 ml cell-
suspension aliquots of 5 3 104 cells. SNA lectin was purchased
from Vector Laboratories. Incubations were carried out in the
dark for 30 min with occasional agitation. In addition, the degree
of specificity of SNA-lectin binding was determined by incubation
with 200 mM lactose. This adequate competitive sugar was incu-
bated with SNA lectin during the incubation time. Flow-cytometry
analysis was performed on a Becton Dickinson FACSCalibur flow
cytometer. Immediately after incubation with lectin, cells were
resuspended in 500 ml of Isoton solution (Becton Dickinson) and
submitted to cytometry analysis. Each analysis was performed
on 20,000 events gated on the region of the HEK cell population
on the basis of light-scatter properties (forward scatter [FSC] versus
side scatter [SSC]). Fluorescence intensity data from the FL1 (green
fluorescence) channel were collected and analyzed with the Cell
Quest Pro software.
RNA Interfering Experiment
Control and TMEM165 siRNA (Dharmacon Smart Pools) were
transfected into HEK cells at a final concentration of 50 nM with
the use of Lipofectamine 2000 according to the manufacturer’s
(Invitrogen) protocol with slight modifications. Cells were tran-
fected in OptiMEM medium in the absence of fetal bovine serum.
Three cycles of transfections were done every 48 hr for the
achievement of maximal knockdown. Cells were transfected
with corresponding siRNAs and collected for analysis 7 days later.Results
Clinical Presentation
The index case (case 1), a boy, is the first child of Georgian
Jewish parents (Figure 1A). Parental consanguinity was
denied. The boy wasmainly affected by growth retardation
(he was unresponsive to growth hormone, which eventu-
ally led to severe dwarfism; he is now 19 years old), psycho-
motor retardation (he began independently walking at
2 years of age), midface hypoplasia, muscular weakness, fat
excess, joint laxity, and hepatosplenomegaly. He showed
increased serum transaminases (the level of aspartate
transaminase [AST] [195–357 U/l; nl < 32] was higher
than that of alanine transaminase [ALT] [43–54 U/l;
nl < 31] and creatine kinase [1,376–1915 U/l; nl < 145)
and partial growth-hormone deficiency. Upon radiological
examination, osteoporosis (MIM 166710) and significant
epiphyseal, metaphyseal, and diaphyseal dysplasia wereAmerican Journal of Human Genetics 91, 15–26, July 13, 2012 17
Figure 1. Family tree, Presentation of Radiolog-
ical Findings, and sTf-IEF Pattern
(A) The family of cases 1 and 2 is the index family
in this study. Radiological image of a knee in case
1 at the age of 17 years (left panel) and of case 3 at
the age of 3.5 years (right panel). Note severe
osteopenia, a very thin bone cortex, broad meta-
physes, and significant dysplasia of the epiph-
yses.
(B) sTf-IEF pattern from a control and from the
individuals under investigation. The number of
negative charges is indicated on the right.evident (Figure 1A). A brain magnetic resonance image
[MRI] revealed white-matter abnormalities and relative
hypoplasia of the pituitary gland.
Case 2, the sister of case 1, presented with similar clinical
features. In addition, she had recurrent, unexplained fever
episodes and died at 14 months of age from an acute infec-
tious shock.
Case 3, the fourth child of an unrelated Georgian Jewish
family, showed the same clinical, biochemical, and radio-
logical features as cases 1 and 2. He had unexplained fever
episodes and transient epilepsy that responded well to
antiepileptic medication, and he needed artificial ventila-
tion (via tracheostomy) up to the age of 4 years because
of an unexplained restrictive lung pathology. Growth-
hormone treatment had no effect on his growth, and
now, at the age of 4 years, he has severe dwarfism.
Case 4 is a Turkish boy. Only limited information is
available on this person. At the age of 9 years, his psycho-
motor level is that of a 4-year-old. His growth is normal.
There is no dysmorphy except for mild rhizomelia, no hep-
atosplenomegaly, and no epilepsy. He has no clear skeletal
anomalies.
Case 5 is an American girl. She presented with a short
stature, facial dysmorphy, wrinkled skin (MIM 278250),
abnormal fat distribution, and dysplastic toenails. She
had amelogenesis imperfecta and skeletal abnormalities,
including osteoporosis, anterior beaking of lumbal verte-
brae, dysplastic vertebrae and ribs, dysplastic fourth meta-
carpals and metatarsals, hypoplasia of femoral heads, and
kyphoscoliosis (a comparison of the main clinical pheno-
types is given in Table 1).
The diagnosis of CDG-II in these cases was established by
standard sTf-IEF showing a marked increase of asialotrans-
ferrin, monosialotransferrin, disialotransferrin, and trisia-
lotransferrin in all cases (Figure 1B).
Structural Analysis of N- and O-Glycans and Golgi
Morphology
Because of the type 2 sTf-IEF pattern, we investigated the
Golgi glycosylation in more detail; we determined the18 The American Journal of Human Genetics 91, 15–26, July 13, 2012structures of the N- and O-linked glycans
on serum glycoproteins from controls and
affected individuals by using mass spec-
trometry (Figure 2). In the affected indi-viduals, there is a relative increase in the undersialylated
and undergalactosylated glycans (NeuAc1Hex4HexNAc4
was at m/z 2,227, Hex5HexNAc4 was at m/z 2,040, and
Hex4HexNAc4 was at m/z 1,836). The presence of these
abnormal ions points to a slight defect in both sialylation
and galactosylation and corroborates the IEF data. Similar
results have been obtained for case 5.15 To test for an
O-glycan deficit, we permethylated, purified, and analyzed
the O-glycans by MALDI-TOF-MS (Figure S1, available
online, represents O-glycans from affected individuals
and control serum). A comparison of the glycan profiles
for the affected individuals and controls revealed no differ-
ences in the relative amounts of glycans, especially in
Hex1HexNAcitol (m/z 534). These results are consistent
with the normal ApoC-III profile and prove the absence
of an O-glycan defect.
Because the N-glycan results point to a Golgi glyco-
sylation defect, the Golgi morphology was investigated.
Staining with Golgi markers TGN46 and GM130 detected
significant alterations in Golgi morphology in fibroblasts
of all affected individuals. Compared to that in controls,
the Golgi apparatus in all affected individuals was found
dilated, and the trans-Golgi network was markedly frag-
mented (Figure 3, see arrows).
Mapping and Gene Identification
Autozygosity mapping in the first family (cases 1 and 2;
Figure 1A) identified two homozygous regions on chromo-
somes 4 and 13 (Figure S2A). According to the haplotype
data from the affected individuals, the interval on chromo-
some 4 was delineated by the SNP markers rs6828553
and rs1505663 and comprised 18 Mb of genomic DNA,
and the interval on chromosome 13 was delimited by the
SNP markers rs10507629 and rs9318228 and comprised
14.8 Mb of genomic DNA. Both autozygous loci were
confirmed by multipoint linkage analysis and had a
Zmax score of 3.6 (Figure S3). The two regions together
contain approximately 140 genes.
To reduce the number of candidate genes, we analyzed
their expression in two affected members, two unaffected
Table 1. Comparison of Clinical Phenotypes
Case 1 Case 2 Case 3 Case 4 Case 5
Ethnicity Jewish Jewish Jewish Turkish American
Consanguinity    þ ND
Lethality  14 months   
Gestational age 40 weeks 38 weeks 40 weeks at term ND
Length at birth P25 P3 P3–P25 P3–P25 ND
Head circumference at birth P50 P50 ND P3–P25 ND
Acquired microcephaly þ þ þ þ ND
Growth retardation þþþ þþ þþþ þ þ
Dysmorphy þ þ þ þ þ
Hypotonia þ þ þ þ ND
Convulsions ND EEG abnormal þ ND ND
Brain MRI abnormal abnormal abnormal ND ND
Eye abnormalities þ þ ND ND þ
Hepatomegaly þ þ þ þ ND
Failure to thrive þ þ þ þ þ
Skeletal dysplasia þ þ þ ND þ
Renal abnormalities    HUS ND
Periods with hyperthermia  þ þ  
Feeding problems/ pseudo-obstruction þ þ  ND ND
Thrombopenia borderline þ þ þ ND
CK elevations in blood þ þ þ þ ND
Transaminases (AST/ALT) þ/ þ/ þ/þ þ/þ ND
The presence (þ) or absence () of each feature is reported for each individual. The following abbreviations are used: þþþ, severe; þþ, moderate; þ, mild; ND,
not done; P, percentile; EEG, electroencephalography; MRI, magnetic resonance image; HUS, haemolytic uremic syndrome (MIM 235400); CK, creatine kinase;
AST, aspartate transaminase; and ALT, alanine transaminase.members, and one unrelated control by using total RNA
from primary fibroblasts. We assayed the differential
expression between affected members and the three
controls by using Affymetrix arrays, and we evaluated
them by using a Student’s t test and SAM,14 KMS, and
HCL with two-class unpaired and two-class paired testing
(Figures S2B, S2C, and S4). Five highly significant genes
that came out in all statistical analyses were sequenced
at the cDNA level, and the result revealed the absence of
exon 4 in the predicted TMEM165 transcript and the inser-
tion of an aberrant 117 bp fragment derived from intron 4.
Sequencing of the coding sequence and the flanking in-
tronic regions of TMEM165 and of the alternative exon
at the genomic level revealed a homozygous mutation,
c.792þ182G>A, in both affected siblings (Figure 4A, left
panel). The mutation activates a cryptic splice donor
site, which leads to two different transcripts: the wild-
type one and an additional one resulting in the re-
placement of exon 4 with a 117 bp intronic sequence
(Figure 4B). The splice prediction program of fruit flies
showed that the normal splice donor has a strength ofThe0.99, whereas the cryptic splice donor site has a strength
of 0.5 without mutation and 0.94 with mutation
c.792þ182G>A. If translated, this aberrant transcript
would lead to a protein shortened by 94 amino acids
and have 27 amino acids changed at the C-terminal part
(Figure 4C).
Sequencing of TMEM165 in a series of 30 individuals
with unsolved CDG-II allowed us to identify three other
individuals with a TMEM165 mutation. Case 3 (P3) is
a Jewish boy whose parents originated from the same
region as the index case, and we detected the same homo-
zygous intronic c.792þ182G>A mutation in his DNA.
Case 4 (P4), who is from a consanguineous Turkish family,
is homozygous for a missense mutation (c.377G>A
[p.Arg126His]) (Figure 4A, middle panel). Case 5 (P5) is
compound heterozygous for a distinct missense mutation
(c.376C>T [p.Arg126Cys]) in the same codon and another
missense mutation (c.910G>A [p.Gly304Arg]) (Figure 4A,
right panel). The arginine at position 126 and the glycine
at position 304 are phylogenetically strictly conserved
and are likely to be pathogenic (Figure S5B).American Journal of Human Genetics 91, 15–26, July 13, 2012 19
Figure 2. Protein N-Glycosylation Deficiencies
MALDI-TOF-MS spectra of the permethylated N-glycans from sera of control and TMEM165-deficient individuals. The symbols repre-
senting sugar residues are as follows: closed square, N-acetylglucosamine; open circle, mannose; closed circle, galactose; open diamond,
sialic acid; and closed triangle, fucose. Linkages between sugar residues have been removed for simplicity.Topography of TMEM165
TMEM165 is predicted to encode a 324 amino acid protein
that seems to be ubiquitously expressed (Figure S6). Sig-
nalIP predicts that this protein contains a signal-peptide
cleavage site at position 33 (Figure S5A). If the signal
peptide is removed, ConPredII methods predict six trans-
membrane domains and a luminal N-tail. Sequence com-20 The American Journal of Human Genetics 91, 15–26, July 13, 2012parison of TMEM165 revealed a high conservation of at
least ~230 residues throughout evolution, and putative
orthologs could be identified in virtually all eukaryotes
and in many bacteria (>300), including cyanobacteria, ac-
tinobacteria (e.g., Mycobacteria), and betaproteobacteria
(e.g., Burkholderia), indicating that TMEM165 has a very
ancient function. All of these putative proteins belong to
Figure 3. Alterations in Golgi Structure
Golgi localization of GM130 (green) and TGN46 (red) in control
and TMEM165-deficient fibroblasts. The cells were double labeled
with antibodies against GM130 and TGN46 and visualized by
confocal microscopy. The arrows point to fragmented Golgi.the UPF0016 family of integral membrane proteins of
unknown function; this family usually contains two copies
of a region that includes an EXGDK/Rmotif (see alignment
in Figure S5B) and that is flanked by two hydrophobic
regions containing 16–20 residues on the N-terminal side
and 8–9 residues on the C-terminal side. Both repeats
also comprise additional hydrophobic regions of approxi-
mately 25–28 and 16–19 residues.
Functional Analysis of TMEM165 Mutations
We used quantitative RT-PCR (qRT-PCR) to investigate the
effects of the mutations on TMEM165 expression by
comparing TMEM165 cDNA levels amplified from mRNA
isolated from control and TMEM165-deficient fibroblasts
cultured in the presence or absence of the translation
inhibitor puromycin. Compared with controls, case 4,
who harbors the missense mutation, had a normal expres-
sion level, whereas affected individuals with the splice
mutation c.792þ182G>A and affected individual P5
with the compound heterozygote mutations showedThea clear reduction in expression of the wild-type transcript
(Figure 5A, left panel). The aberrant transcript is detectable
only in small amounts in controls, whereas its expression
level is high in all affected individuals harboring the
splice mutation c.792þ182G>A (Figure 5A, right panel).
Culturing control and TMEM165-deficient fibroblasts in
the presence of puromycin did not drastically change the
expression level except for in individual P5, in whom the
amount of wild-type transcript was restored. However, in
the three affected individuals with the splice mutation,
a high increase in the amount of alternative transcript
was observed, suggesting that the aberrant splice variant
is subject to nonsense-mediated decay.
To investigate the effect of the mutations on TMEM165,
we performed immunoblotting in control and TMEM165-
deficient fibroblasts. As shown in Figure 5B, an extremely
low level of full-length TMEM165 was detected in affected
individuals with the truncating mutation. However, no
shortened protein was observed, suggesting that the trun-
cated protein, if translated, was unstable and prone to
degradation. Moreover, only 25% of the immunoreactivity
was recovered in case 4 with the missense mutation,
suggesting that the mutant protein is also unstable
(Figure 5B). In case 5, only a slight decrease in TMEM165
stability was observed.
We next compared the subcellular localizations of wild-
type and mutated TMEM165 in fibroblasts by confocal
microscopy. At the steady state, TMEM165 shows a clear
perinuclear Golgi-like distribution (Figure 5C). As expected
from immunoblot analysis, the TMEM165-deficient indi-
viduals showed a much weaker signal than did the
controls. However, a faint Golgi localization could be
seen in all affected individuals (Figure 5C).
Subcellular TMEM165 Localization
As depicted above, TMEM165 displays a perinuclear Golgi-
like distribution. In order to gain insight into its precise
Golgi localization, we used the microtubule-depolymeriz-
ing agent nocodazole, which has been shown to disrupt
the Golgi complex. Nocodazole treatment is known to
disperse Golgi markers into discrete puncta and has there-
fore been used for the localization of proteins to distinct
Golgi subcompartments.16,17 Double labeling of nocoda-
zole-treated cells with cis-Golgi (GM130) and trans-Golgi
(GalT) markers showed clear, although incomplete, segre-
gation of the two markers (Figure 6). After nocodazole
treatment, TMEM165 showed a relatively low degree of
colocalization with GM130 but a rather complete colocal-
ization with GalT. The level of colocalization was quanti-
fied as the area occupied by the colocalizing spots in
the image as a percentage of the total labeled spots.
Consistent with the qualitative data, these results showed
a much higher degree of colocalization for TMEM165
versus GalT (73 5 4%) than for TMEM165 versus GM130
(375 8%). These results suggest that TMEM165 is present
in the late Golgi (trans) rather than in the early Golgi (cis
and median).American Journal of Human Genetics 91, 15–26, July 13, 2012 21
Figure 4. TMEM165Mutations
(A) In the left panel is the sequence align-
ment of the genomic DNA fragment from
a control C and cases P1, P2, and P3 homo-
zygous for the G>A transition at position
c.792þ182. In the middle and right panels
is the sequence alignment of the cDNA
fragment from a control C and cases P4
and P5. P4 is homozygous for the G>A
transition at position c.377, and P5 is
compound heterozygous for the C>T tran-
sition at position 376 and the G>A transi-
tion at position 910. Nucleotides affected
by the mutations and the predicted effects
on protein length are indicated above each
sequence.
(B) Schematic representation of the pre-
dicted genomic (top) and cDNA (bottom)
structure of TMEM165 in the control and
cases P1, P2, and P3. Coding exons are
shown in blue boxes, and introns (not
drawn to scale) are represented by lines.
The beginning and end of the open
reading frame are labeled; the numbering
above each exon is based on coding nucle-
otides. The red box represents the alterna-
tive exon 4 (40) used in cases P1, P2, and P3.
(C) Predicted effect of the c.792þ182G>A
mutation on TMEM165. Sequence align-
ment was compared between wild-type
TMEM165 and mutant TMEM165. The
amino acids that changed as a result of
the mutation are highlighted in yellow.
The mutated TMEM165 is truncated and
shortened by 94 amino acids.Analysis of Glycosylation Defects
The impact of TMEM165 on Golgi glycosylation was
studied in TMEM165-deficient fibroblasts. Surprisingly,
we did not find a general glycosylation deficiency (data
not shown). To further investigate this link, we used siRNA
to study whether defective TMEM165 was sufficient to
cause a Golgi glycosylation deficiency. To this goal, HEK
cells were treated with TMEM165 siRNA for 7 days. As
shown in Figure 7A, compared with controls, HEK cells
treated with siRNA showed a strong (>90%) decrease in
the level of TMEM165 after 7 days, whereas actin protein
levels remained unchanged. This has been confirmed by
immunofluorescence microscopy in which only a few cells
showed a Golgi staining (Figure 7B) and by fluorescence-
activated cell sorting (FACS) analysis (data not shown).
To investigate the Golgi glycosylation status in
siTMEM165 HEK cells, we used SNA-FITC-conjugated
lectin for flow-cytometry analysis with and without
200 mM lactose. For each histogram, the fluorescence
peak corresponding to SNA binding in the presence of
200 mM lactose (nonspecific binding) is represented
(Figure 7C). Specific binding was calculated as the differ-
ence between the mean fluorescence intensities (Fig-
ure 7D) of total and nonspecific peaks. Weak fluorescence
intensity shifts for specific SNA binding were observed for
TMEM165-knockdown HEK cells (compared to controls,
they showed a 25% decrease in fluorescence) (Figure 7E).22 The American Journal of Human Genetics 91, 15–26, July 13, 2012The observed decrease in sialylation indicates disturbed
terminal Golgi glycosylation in TMEM165-depleted cells.
To confirm this finding, we determined the steady-state
glycosylation status of the lysosomal resident protein
Lamp2 (Figure 7F). After 7 days of TMEM165 knockdown,
the fact that the gel mobility of Lamp2 was altered indi-
cated the presence of underglycosylated protein species.
To confirm that the increase in gel mobility was caused
by defective glycosylation, we subjected both control and
TMEM165-knockdown cell lysates to PNGase F treatment
(Figure 7F). We found that deglycosylation of all forms of
Lamp2 produced a single polypeptide of the same relative
molecular mass, indicating that N-glycosylation was
affected.Discussion
We have identified TMEM165 (also called TPARL) as
a gene encoding a protein of unknown function. Muta-
tions in this gene are responsible for a previously unde-
scribed type of CDG-II. The identification of the gene
was achieved by a combination of homozygosity mapping
and expression profiling. In total, four different mutations
in TMEM165 were identified. The results point to an
important role for TMEM165 in Golgi glycosylation and
Golgi morphology maintenance.
Figure 5. Functional Analyses of
TMEM165 Mutations
(A) Quantification of the wild-type (left
panel) and alternative (alt) TMEM165
transcripts (right panel) in controls and
affected individuals by qPCR with (þ)
and without () puromycin. Expression
is measured relative to a housekeeping
gene. Values plotted with a wild-type
control group untreated with puromycin
are set to 1. Error bars represent 5 SEM.
Expression of TMEM165 in control and
TMEM165-deficient fibroblasts: steady-
state levels of expression (B) and intracel-
lular distribution (C).
(B) Immunoblots of whole-cell lysates
from control (C) and TMEM165-deficient
(P) fibroblasts. Actin levels were used as
a loading control.
(C) Control and TMEM165-deficient fibro-
blasts were processed for immunofluores-
cence microscopy with TMEM165 anti-
bodies. For comparison, images were
collected under identical settings.The precise role of TMEM165 needs to be further deter-
mined, but on the basis of the predicted topology and
the comparative phylogeny, some predictions regarding
its function can be made. TMEM165 includes seven trans-
membrane domains—or six if one assumes that a signal
peptide is cleaved off. The protein is extremely well
conserved during evolution. Almost all orthologs that we
could identify are integral membrane proteins containing
two copies of an EXGDK/R motif flanked by two hydro-
phobic regions. Iterated Blast searches indicated that
TMEM165 is distantly related to bacterial sodium-phos-
phate transporters, which, however, do not contain theThe American Journal of Hutypical EXGDK/R motif that is
present in TMEM165. This finding,
as well as an analysis with the ProtFun
software, points to TMEM165 as
being a transporter.18
The fact that the highly conserved
motifs, which are presumably critical
for the function of TMEM165, com-
prise more negative than positive
charges suggests that the transported
species is a cation, possibly a proton.
For comparison, it has been shown
that protonatable carboxylic groups
of several aspartates and a glutamate
and a prosthetic group bound to a
lysine via a Schiff base are important
for the proton-pumping action for
bacteriorhodopsin, the best character-
ized proton-pump protein. A nearby
positively charged arginine residue
could be involved in controlling pKa
of the asparagine by acting as a central
proton donor and acceptor.19Another argument supporting TMEM165 as a proton
pump stems from its expression pattern. It is highly
expressed in the lactating mammary gland (BioGPS
database). The synthesis of lactose involves the genera-
tion of two protons inside the Golgi apparatus; one is
generated during the transfer of galactose from UDP-Gal
onto glucose, and the other is created during the
subsequent hydrolysis of UDP to UMP and inorganic
phosphate. Because the lactose concentration is around
100 mM in milk, this represents a significant proton
load. A good way of getting rid of this proton load
would be a passive transport to the cytosol, where theman Genetics 91, 15–26, July 13, 2012 23
Figure 6. Subcellular Localization of Wild-Type
TMEM165
Indirect double immunofluorescence staining of
control fibroblasts treated in the absence and
presence of nocodazole (þ Noc). The cells were
then double labeled with antibodies against
TMEM165 and with antibodies against either
GalT or GM130. The cells were then examined
by confocal microscopy. In the presence of noco-
dazole, close examination of the overlays shows
that the colocalization of TMEM165 with GalT
is more complete than it is with GM130.protons will be ‘‘reused’’ in the course of UDP-Gal
synthesis.
A third argument is derived from the genomic organiza-
tion of the TMEM165 ortholog in certain bacteria. Indeed,
bacterial genes are frequently organized in operons and
often encode proteins that are functionally related.
Inspection of the genomic environment of the bacterial
orthologs of TMEM165 indicated that, in most cases, these
orthologs were isolated open reading frames. However, the
TMEM165 orthologs appeared to belong to the same
operon as a putative guanosine deaminase and adenosine
deaminase in Ralstonia solanacearum, and it was just
downstream of operons encoding these enzymes in
several other species (Cupriavidus metallidurans, Burkholde-
ria cepacia, Burkholderia cenocepacia, and Burkholderia
pseudomallei). Adenosine deaminase and guanosine deam-
inase, which are readily protonated at a neutral pH,
presumably cause alkalinization of the cytosol. We specu-
late that the TMEM165 ortholog allows protons to flow
in from the extracellular medium and thereby neutralizes
the alkaline load. The optimal pH in secretory and endo-24 The American Journal of Human Genetics 91, 15–26, July 13, 2012cytic organelles has to be maintained by
the balance between active protein pump-
ing and passive proton efflux. It is therefore
possible that TMEM165 is responsible for
passive proton leakage within the secretory
pathway.
The link between the TMEM165 defect
and the Golgi glycosylation deficiency is
far from solved, andwe found some discrep-
ancies. Indeed, although a severe glycosyla-
tion deficiency was observed from sTf-IEF,
only a slight deficiency was found from
a MALDI-TOF analysis of total serum
N-glycoproteins. Moreover, a glycosylation
analysis of TMEM165-deficient fibroblasts
was normal. This could be the result
of a functional compensation in (slowly
growing) cells in culture, although it should
be mentioned that fibroblasts are not good
models for the study of glycosylation. We
showed that a depletion of TMEM165 in
HEK cells does lead to a mild deficiency of
glycosylation. Still, the observed hypogly-cosylation could be secondary, i.e., the primary molecular
defect could reside outside the glycosylation machinery.
The major clinical findings in the individuals with
a homozygous splice mutation are severe psychomotor
retardation, major skeletal dysplasia, and, in the surviving
individuals, pronounced dwarfism. Interestingly, the indi-
viduals harboring missense mutations have a milder
disease and lack the skeletal phenotype. The possibility
that the skeletal phenotype is not due to the mutations
in TMEM165 but to a concomitant defect in a neighboring
gene cannot be completely excluded. The answer to this
question will have to await the development of specific
animal knockout models.
Finally, it is not without importance that, in view of the
present hype around exome sequencing, the causal muta-
tion in the index family would never have been identified
if the affected individuals’ samples had been directly sub-
jected to exome sequencing. Hence, we wish to underline
that the combination of autozygositymapping and expres-
sion analysis is still useful. Of course, it has limitations,
e.g., we were fortunate to deal with a mutation that affects
Figure 7. Depletion of TMEM165 Slightly Affects Golgi Glycosylation
(A) HEK cells were transfected with nontarget siRNA (‘‘Control’’) or siRNA targeted to TMEM165 (‘‘siRNA’’). Seven days after transfection,
cells were lysed and equivalent amounts of homogenate were subjected to SDS PAGE and immunoblotted with antibodies against
TMEM165 and actin.
(B) Indirect immunofluorescence staining of the siRNA TMEM165 HEK cells with the use of anti-TMEM165.
(C) HEK cells were transfected with nontarget siRNA (‘‘Control’’) or siRNA targeted to TMEM165 (‘‘siRNA’’). Seven days after transfection,
cells were harvested, permeabilized, and incubated with FITC-labeled SNA for flow-cytometry analysis. Histogram plots of control (blue
line) and siRNA-TMEM165-transfected (red line) HEK cells analyzed for SNA binding and incubated with FITC-labeled SNA are shown.
For each condition, the fluorescence peak corresponding to SNA binding in the presence of 200 mM lactose is represented (nonspecific
binding: green line for control and violet line for siRNA). Specific binding was calculated as the difference between the mean fluores-
cence intensities of total and nonspecific binding peaks (see D).
(E) The results were expressed as the percentages of specific lectin binding to cells. In the calculation, specific lectin binding to control
cells, which corresponds to the difference between the total and the nonspecific-binding peaks, was considered as 100%.
(F) HEK cells were transfected with nontarget siRNA (‘‘Control’’) or siRNA targeted to TMEM165 (‘‘siRNA’’). Seven days after transfection,
cells were lysed (incubated or not with PNGase [1,000 U per sample]), and equivalent amounts of homogenate were subjected to SDS and
immunoblotted with antibodies against Lamp2.the expression level of the mRNA. It is remarkable that the
proposed strategy has rarely been used or reported in the
literature.
In conclusion, we have identified a protein that is asso-
ciated with protein hypoglycosylation and that seems to
be of prime importance for Golgi structure, maintenance,
and/or pH.Supplemental Data
Supplemental data include six figures and can be found with this
article online at http://www.cell.com/AJHG.TheAcknowledgments
We are indebted to Ragna Sannerud for providing advice and tools
for the imaging experiments and to Professor Eric Berger, Professor
Thierry Hennet, Ellen Reynders, Professor Jack Rohrer, and
many others for helpful discussions. The work was supported by
grant G.0553.08 from the FWO (Fonds voor Wetenschappelijk
Onderzoek, Vlaanderen, Belgium) and grant 12540 from the
AFM (Association Franc¸aise contre les Myopathies, France) to
G.M.; a PEPS-CNRS (Projets Exploratoires/Premier Soutien du
Centre National de la Recherche Scientifique, France), a Marie
Curie Reintegration Grant (VTG-CDG), and an Agence Nationale
Recherche Jeune Chercheur to F.F.; grants from the F.R.S.-FNRSAmerican Journal of Human Genetics 91, 15–26, July 13, 2012 25
(Fonds de la Recherche Scientifique, Wallonie), la Communaute´
Franc¸aise de Wallonie-Bruxelles, and la Loterie Nationale
(Belgium) to M.V.; the Interuniversity Attraction Poles Program
(network 6/05) of the Belgian Science Policy (Belgium) to E.V.S.,
G.M., and M.V.; grant R01DK55615 and The Rocket Fund to
H.F.; the European Commission (Sixth Framework Program,
contract LSHM-CT.2005-512131 to EUROGLYCANET) to G.M.
and E.V.S.; and the Ko¨rber Stiftung to J.J., E.V.S., and G.M. M.A.
is a ‘‘Scientific Logistics Manager’’ of the F.R.S.-FNRS. The authors
thank the Genomics/Transcriptomics platform of Universite´ cath-
olique de Louvain for performing the Affymetrix chip experiments
and the Bioimaging Core Facility of Lille (Institut de Recherche In-
terdisciplinaire, CNRS).
Received: January 9, 2012
Revised: April 2, 2012
Accepted: May 1, 2012
Published online: June 7, 2012Web Resources








1. Jaeken, J., and Matthijs, G. (2007). Congenital disorders of
glycosylation: A rapidly expanding disease family. Annu.
Rev. Genomics Hum. Genet. 8, 261–278.
2. Jaeken, J., Hennet, T., Matthijs, G., and Freeze, H.H. (2009).
CDG nomenclature: Time for a change!. Biochim. Biophys.
Acta 1792, 825–826.
3. Schachter, H., and Freeze, H.H. (2009). Glycosylation diseases:
Quo vadis? Biochim. Biophys. Acta 1792, 925–930.
4. Foulquier, F. (2009). COG defects, birth and rise!. Biochim.
Biophys. Acta 1792, 896–902.
5. Wu, X., Steet, R.A., Bohorov, O., Bakker, J., Newell, J., Krieger,
M., Spaapen, L., Kornfeld, S., and Freeze, H.H. (2004). Muta-
tion of the COG complex subunit gene COG7 causes a lethal
congenital disorder. Nat. Med. 10, 518–523.
6. Foulquier, F., Ungar, D., Reynders, E., Zeevaert, R., Mills, P.,
Garcı´a-Silva, M.T., Briones, P., Winchester, B., Morelle, W.,
Krieger, M., et al. (2007). A new inborn error of glycosylation
due to a Cog8 deficiency reveals a critical role for the Cog1-
Cog8 interaction in COG complex formation. Hum. Mol.
Genet. 16, 717–730.
7. Foulquier, F., Vasile, E., Schollen, E., Callewaert, N., Rae-
maekers, T., Quelhas, D., Jaeken, J., Mills, P., Winchester, B.,
Krieger, M., et al. (2006). Conserved oligomeric Golgi complex26 The American Journal of Human Genetics 91, 15–26, July 13, 2012subunit 1 deficiency reveals a previously uncharacterized
congenital disorder of glycosylation type II. Proc. Natl. Acad.
Sci. USA 103, 3764–3769.
8. Kranz, C., Ng, B.G., Sun, L., Sharma, V., Eklund, E.A., Miura, Y.,
Ungar, D., Lupashin, V., Winkel, R.D., Cipollo, J.F., et al.
(2007). COG8 deficiency causes new congenital disorder of
glycosylation type IIh. Hum. Mol. Genet. 16, 731–741.
9. Reynders, E., Foulquier, F., Lea˜o Teles, E., Quelhas, D., Morelle,
W., Rabouille, C., Annaert, W., and Matthijs, G. (2009). Golgi
function and dysfunction in the first COG4-deficient CDG
type II patient. Hum. Mol. Genet. 18, 3244–3256.
10. Paesold-Burda, P., Maag, C., Troxler, H., Foulquier, F., Klei-
nert, P., Schnabel, S., Baumgartner, M., and Hennet, T.
(2009). Deficiency in COG5 causes a moderate form of
congenital disorders of glycosylation. Hum. Mol. Genet.
18, 4350–4356.
11. Kornak, U., Reynders, E., Dimopoulou, A., van Reeuwijk, J.,
Fischer, B., Rajab, A., Budde, B., Nu¨rnberg, P., Foulquier, F.,
Lefeber, D., et al; ARCL Debre´-type Study Group. (2008).
Impaired glycosylation and cutis laxa caused by mutations
in the vesicular Hþ-ATPase subunit ATP6V0A2. Nat. Genet.
40, 32–34.
12. Nannya, Y., Sanada, M., Nakazaki, K., Hosoya, N., Wang, L.,
Hangaishi, A., Kurokawa, M., Chiba, S., Bailey, D.K., Kennedy,
G.C., and Ogawa, S. (2005). A robust algorithm for copy
number detection using high-density oligonucleotide single
nucleotide polymorphism genotyping arrays. Cancer Res.
65, 6071–6079.
13. Yamamoto, G., Nannya, Y., Kato, M., Sanada, M., Levine, R.L.,
Kawamata, N., Hangaishi, A., Kurokawa, M., Chiba, S., Gilli-
land, D.G., et al. (2007). Highly sensitive method for genome-
wide detection of allelic composition in nonpaired, primary
tumor specimens by use of Affymetrix single-nucleotide-
polymorphism genotyping microarrays. Am. J. Hum. Genet.
81, 114–126.
14. Tusher, V.G., Tibshirani, R., and Chu, G. (2001). Significance
analysis of microarrays applied to the ionizing radiation
response. Proc. Natl. Acad. Sci. USA 98, 5116–5121.
15. Miura, Y., Hato, M., Shinohara, Y., Kuramoto, H., Furukawa, J.,
Kurogochi, M., Shimaoka, H., Tada, M., Nakanishi, K., Ozaki,
M., et al. (2008). BlotGlycoABCTM, an integrated glycoblot-
ting technique for rapid and large scale clinical glycomics.
Mol. Cell. Proteomics 7, 370–377.
16. Chavrier, P., Parton, R.G., Hauri, H.P., Simons, K., and Zerial,
M. (1990). Localization of low molecular weight GTP binding
proteins to exocytic and endocytic compartments. Cell 62,
317–329.
17. Ullrich, O., Reinsch, S., Urbe´, S., Zerial, M., and Parton, R.G.
(1996). Rab11 regulates recycling through the pericentriolar
recycling endosome. J. Cell Biol. 135, 913–924.
18. Demaurex, N. (2002). pH Homeostasis of cellular organelles.
News Physiol. Sci. 17, 1–5.
19. Krogh, A., Larsson, B., von Heijne, G., and Sonnhammer, E.L.
(2001). Predicting transmembrane protein topology with
a hidden Markov model: Application to complete genomes.
J. Mol. Biol. 305, 567–580.
